Maksim Mamonkin – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 08 Mar 2023 10:35:18 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Maksim Mamonkin – VJRegenMed https://mirror.vjregenmed.com 32 32 Exploring the potential role of CD7-targeting CAR-T cells in T-ALL https://mirror.vjregenmed.com/video/ylmw43tyjhq-exploring-the-potential-role-of-cd7-targeting-car-t-cells-in-t-all/ Wed, 08 Mar 2023 10:35:18 +0000 https://mirror.vjregenmed.com/video/ylmw43tyjhq-exploring-the-potential-role-of-cd7-targeting-car-t-cells-in-t-all/ Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, shares some insights into the promise of CD7-targeting CAR-T therapies for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL). Dr Mamonkin explains methods used to develop these products, and further highlights the promising activity that has been observed in ongoing clinical trials. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]> The potential of gene-edited effector cell therapy https://mirror.vjregenmed.com/video/kzshhs-upwq-the-potential-of-gene-edited-effector-cell-therapy/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/kzshhs-upwq-the-potential-of-gene-edited-effector-cell-therapy/ Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discusses gene-edited effector cell therapy, and its potential to improve the outcomes of T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies https://mirror.vjregenmed.com/video/lmfspyde8pm-cd5-and-cd7-directed-car-t-cells-for-pediatric-t-cell-malignancies/ Wed, 30 Sep 2020 12:05:05 +0000 http://13.40.107.223/video/lmfspyde8pm-cd5-and-cd7-directed-car-t-cells-for-pediatric-t-cell-malignancies/ Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, outlines the use of CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies, including the results of a first-in-man study of CD5 CAR T-cells in the treatment of T-cell malignancies, as well as challenges associated with bringing these innovative therapies to the clinic. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>